Construction of a live-attenuated bivalent vaccine virus against human parainfluenza virus (PIV) types 1 and 2 using a recombinant PIV3 backbone

Vaccine

Volumn 19, Issue 27, 2001, Pages 3620-3631

  Tao, Tao ^a   Skiadopoulos, Mario H ^a   Davoodi, Fatemeh ^a   Surman, Sonja R ^a   Collins, Peter L ^a   Murphy, Brian R ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Human parainfluenza virus (PIV); Recombinant PIV3 backbone; Vaccine

Indexed keywords

CIS ACTING ELEMENT; HN PROTEIN; HYBRID PROTEIN; LIVE VACCINE; PARAINFLUENZA VACCINE; RECOMBINANT PARAINFLUENZA VIRUS 3 PROTEIN; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS PROTEIN; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; GENE CASSETTE; GENE EXPRESSION; GENE INSERTION; GENETIC TRANSCRIPTION; HAMSTER; HUMAN; HUMAN CELL; IN VITRO STUDY; NONHUMAN; OPEN READING FRAME; PARAINFLUENZA VIRUS 1; PARAINFLUENZA VIRUS 2; PARAINFLUENZA VIRUS 3; PRIORITY JOURNAL; PROVOCATION TEST; RESPIRATORY TRACT INFECTION; RNA VIRUS INFECTION; TEMPERATURE SENSITIVITY; TREATMENT OUTCOME; VACCINE PRODUCTION; VIRUS HYBRID; VIRUS RECOMBINATION; VIRUS REPLICATION;

ANIMALS; CELL LINE; CRICETINAE; HUMANS; PARAINFLUENZA VACCINES; PARAINFLUENZA VIRUS 1, HUMAN; PARAINFLUENZA VIRUS 2, HUMAN; RESPIROVIRUS INFECTIONS; VACCINES, ATTENUATED; VACCINES, DNA; VACCINES, SYNTHETIC;

EID: 0035859304     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(01)00101-3     Document Type: Article

References (59)

1. Parainfluenza Viruses
2. African green monkeys provide a useful nonhuman primate model for the study of human parainfluenza virus types-1, -2, and -3 infection
3. A live attenuated recombinant chimeric parainfluenza virus (PIV) candidate vaccine containing the hemagglutinin-neuraminidase and fusion glycoproteins of PIV1 and the remaining proteins from PIV3 induces resistance to PIV1 even in animals immune to PIV3
4. Respiratory syncytial virus
5. Current approaches to the development of vaccines effective against parainfluenza and respiratory syncytial viruses
6. Prevalence of various respiratory viruses in the middle ear during acute otitis media
7. Epidemiology and clinical impact of parainfluenza virus infections in otherwise healthy infants and young children < 5 years old
8. Cold-passaged, temperature-sensitive mutants of human respiratory syncytial virus (RSV) are highly attenuated, immunogenic, and protective in seronegative chimpanzees, even when RSV antibodies are infused shortly before immunization
9. Comparison of the immunogenicity and efficacy of a replication- defective vaccinia virus expressing antigens of human parainfluenza virus type 3 (HPIV3) with those of a live attenuated HPIV3 vaccine candidate in rhesus monkeys passively immunized with PIV3 antibodies
10. Recovery of infectious human parainfluenza virus type 3 from cDNA
11. Mutations in the C, D, and V open reading frames of human parainfluenza virus type 3 attenuate replication in rodents and primates
12. Three amino acid substitutions in the L protein of the human parainfluenza virus type 3 cp45 live attenuated vaccine candidate contribute to its temperature sensitive and attenuation phenotypes
13. Identification of mutations contributing to the temperature-sensitive, cold-adapted, and attenuation phenotypes of the live-attenuated cold-passage 45 (cp45) human parainfluenza virus 3 candidate vaccine
14. Generation of a parainfluenza virus type 1 vaccine candidate by replacing the HN and F glycoproteins of the live-attenuated PIV3 cp45 vaccine virus with their PIV1 counterparts
15. An infectious clone of human parainfluenza virus type 3
16. Accommodation of foreign genes into the Sendai virus genome: Sizes of inserted genes and viral replication
17. Recombinant vesicular stomatitis virus expressing respiratory syncytial virus (RSV) glycoproteins: RSV fusion protein can mediate infection and cell fusion
18. A recombinant measles virus expressing hepatitis B virus surface antigen induces humoral immune responses in genetically modified mice
19. A recombinant measles virus expressing biologically active human interleukin-12
20. Human parainfluenza virus type 3 (PIV3) expressing the hemagglutinin protein of measles virus provides a potential method for immunization against measles virus and PIV3 in early infancy
21. Recovery of negative-strand RNA viruses from plasmid DNAs: A positive approach revitalizes a negative field
22. High-efficiency incorporation of functional influenza virus glycoproteins into recombinant vesicular stomatitis viruses
23. Long nucleotide insertions between the HN and L protein coding regions of human parainfluenza virus type 3 yield viruses with temperature- sensitive and attenuation phenotypes
24. Experience with the Vero cell line
25. Failure of attenuated temperature-sensitive influenza A (H3N2) virus to induce heterologous interference in humans to parainfluenza type 1 virus
26. Recovery of a fully viable chimeric human parainfluenza virus (PIV) type 3 in which the hemagglutinin-neuraminidase and fusion glycoproteins have been replaced by those of PIV type 1
27. Replication-deficient vaccinia virus encoding bacteriophage T7 RNA polymerase for transient gene expression in mammalian cells
28. Evaluation of a subcutaneously implanted chamber for antibody production in rabbits
29. Purification of human respiratory syncytial virus: Superiority of sucrose gradient over percoll, renografin, and metrizamide gradients
30. Replacement of the ectodomains of the hemeagglutinin-neuraminidase (HN) and fusion (F) glycoproteins of recombinant parainfluenza virus type 3 (PIV3) with their counterparts from PIV2 yields attenuated PIV2 vaccine candidates
31. Localization of functional sites on the hemagglutinin-neuraminidase glycoprotein of Sendai virus by sequence analysis of antigenic and temperature-sensitive mutants
32. Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3-6 months after immunization
33. Antigenic variation in the hemagglutinin-neuraminidase protein of human parainfluenza type 3 virus
34. The rule of six, a basic feature for efficient replication of Sendai virus defective interfering RNA
35. Minimum protein requirements for transcription and RNA replication of a minigenome of human parainfluenza virus type 3 and evaluation of the rule of six
36. Attenuation of the recombinant human parainfluenza virus type 3 cp45 candidate vaccine virus is augmented by importation of the respiratory syncytial virus cpts530 L polymerase mutation
37. A live attenuated chimeric recombinant parainfluenza virus (PIV) encoding the internal proteins of PIV type 3 and the surface glycoproteins of PIV type 1 induces complete resistance to PIV1 challenge and partial resistance to PIV3 challenge
38. Molecular mechanisms of serum resistance of human influenza H3N2 virus and their involvement in virus adaption in a new host
39. Recovery of infectious respiratory syncytial virus expressing an additional, foreign gene
40. Interferon gamma expressed by a recombinant respiratory syncytial virus attenuates virus replication in mice without compromising immunogenicity
41. Vaccination with a recombinant vesicular stomatitis, virus expressing an influenza virus hemagglutinin provides complete protection from influenza virus challenge
42. Attenuated vesicular stomatitis viruses as vaccine vectors
43. Construction of a novel virus that targets HIV-1-infected cells and controls HIV1 infection
44. The minimal conserved transcription stop-start signal promotes stable expression of a foreign gene in vesicular stomatitis virus
45. Foreign glycoproteins expressed from recombinant vesicular stomatitis viruses are incorporated efficiently into virus particles
46. Recovery of infectious SV5 from cloned DNA and expression of a foreign gene
47. Sendai virus-based expression of HIV-1 gp120: Reinforcement by the V (-) version
48. Specific targeting to CD4+ cells of recombinant vesicular stomatitis viruses encoding human immunodeficiency virus envelope proteins
49. Highly stable expression of a foreign gene from rabies virus vectors
50. Recombinant human respiratory syncytial virus (RSV) from cDNA and construction of subgroup A and B chimeric RSV
51. Creation of an infectious recombinant Sendai virus expressing the firefly luciferase gene from the 3′ proximal first locus
52. Chimeric measles viruses with a foreign envelope
53. Ambisense gene expression from recombinant rabies virus: Random packaging of positive- and negative-strand ribonucleoprotein complexes into rabies virions
54. Large quantity production with extreme convenience of human SDF-1 alpha and SDF-1 beta by a Sendai virus vector
55. Attenuated poliovirus strain as a live vector: Expression of regions of rotavirus outer capsid protein VP7 by using recombinant Sabin 3 viruses
56. Double-subgenomic Sindbis virus recombinants expressing immunogenic proteins of Japanese encephalitis virus induce significant protection in mice against lethal JEV infection
57. A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in healthy infants and children
58. A live attenuated bovine parainfluenza virus type-3 vaccine is safe, infectious, immunogenic, and phenotypically stable in infants and children
59. Recombinant respiratory syncytial virus (RSV) bearing a set of mutations from cold-passaged RSV is attenuated in chimpanzees